PEFs (IRE and nsPEF) drive anti-tumor responses by systemically reshaping the myeloid immune landscape: They significantly reduce MDSCs proportions (19, 20) and inhibit CCR2+TAM-mediated immunosuppression (104), while driving the sphingolipid metabolism-mediated differentiation of Ly6c2+ monocytes into dendritic cells (53). This evidence concerns the gene CCR2 and neoplasm.